Clinical Trial Update: Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Phase 3 study evaluating ultrasound scores as an indicator of response to subcutaneous abatacept in rheumatoid arthritis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ORENCIA (ABATACEPT)

Snippet

Sponsor: University of California, Los Angeles | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2015-01-30